Fremont, California 94555

  • Graft Vs Host Disease


Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.


Inclusion Criteria: - Recipient of single allogeneic stem cell transplant from any donor type - Time post transplant less than 100 days - Received no treatment for GVHD other than steroids Exclusion Criteria: - Recipient of second allogeneic stem cell transplant or subsequent lymphocyte product from the donor post transplant - IBMTR index less than A - Received any murine product in the past - Diagnosed with chronic GVHD - Received Atgam later than day 10 post transplant - Change to prophylactic regimen for acute GVHD within 72 hours of randomization



Primary Contact:


Backup Contact:


Location Contact:

Fremont, California 94555
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.